Expert Interview

This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

A Third View: Delving into the Phase 3 THRIVE Clinical Trial topline data on Veligrotug (VRDN-001) in Patients with Active Thyroid Eye Disease

Ticker(s): VRDN

Who's the expert?

Institution: East Coast Medical Associates

Treats 30 patients with Thyroid Eye Disease
treats 15 patients with chronic TED and has prescribed TEPEZZA for 10 patients
familiar with the recently announced positive topline results from the Phase 4 clinical trial (NCT04583735) evaluating TEPEZZA for the treatment of adults with chronic TED and low CAS

Interview Goal

to discuss the current treatment landscape and the potential of VRDN-001 an IGF-1 receptor antagonist being developed by Veridian Therapeutics for the treatment of thyroid eye disease.

Do you want answers to these questions?

Yes! Sign me up for FREE
so I can learn more Yes.
LOGIN!

Click Here to Access
This Project

Slingshot Insights Explained

JOIN FOR FREE TODAY

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.

Reason

Click Here to Access
This Project

*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.